{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"134"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"242"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"105"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"69"}],"title":"Unknown"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"553"}],"units":"Participants"}],"description":"The number of participants with evidence of Complete Response (CR) (the disappearance of all target and non-target lesions), Partial Response (PR) (at least a 30% decrease in the sum of the longest diameters \\[LD\\] of target lesions, taking as a reference the Baseline sum LD), Stable Disease (small changes that do not meet previously given criteria, taking as reference the smallest sum LD since the treatment started), or Progressive Disease (a \\>=20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started) was evaluated by an independent review per RECIST, Version 1.","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received.","reportingStatus":"POSTED","timeFrame":"From randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 39 months","title":"Overall Response Rate (ORR) as Assessed by Independent Review","type":"SECONDARY","unitOfMeasure":"Participants"}